DeepMind spinout Isomorphic Labs raised $2.1 billion as Demis Hassabis now points to first AI-designed drugs entering human trials by late 2026.
Apa yang berubah
The company uses IsoDDE, a pipeline combining structure prediction, molecule generation, binding prediction and ADMET assessment.
Thrive, Alphabet-linked funds, MGX, Temasek and a UK sovereign AI fund joined the round, showing the capital intensity of AI drug discovery.
Mengapa penting
Entering clinical trials is not the same as approval; the pharmaceutical probability game remains slow and harsh.
Yang perlu dipantau
Sinyal yang penting bukan hanya angka besar di judul, melainkan apakah produk, kontrak, atau pergeseran platform ini bisa berulang dalam dua kuartal berikutnya.
Sumber: CocoLoop